title: [Evaluation of multimodality therapy for synchronous liver metastases of gastric cancer].
abstract: We evaluated the significance of multimodality therapy for cases of liver metastases of gastric cancer. Accumulated survival rate and median survival time were analyzed for twenty cases of such gastric cancer. Survival rates of H1+H2 group and hepatic resection (HR) group were higher than that of H3 group and non-HR group. MST of HR group and hepatic arterial infusion (HAI) group were longer than that of non-HR group and non-HAI group. Survival rate of HAI group was higher than that of non-HAI group among eleven cases of HR group. On the other hand, survival rate of HR group was higher than that of non-HR group among eleven cases of HAI group. These results suggested that HAI chemotherapy after hepatic resection for gastric cancer patients with synchronous liver metastasis would improve prognosis.
authors.affiliation: Dept. of Surgery, Hiroshima City Hospital.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sasaki
authors.forename: Motoki
authors.initials: M
authors.lastname: Ninomiya
authors.forename: Shuya
authors.initials: S
authors.lastname: Yano
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Umeoka
authors.forename: Masao
authors.initials: M
authors.lastname: Harano
authors.forename: Hideki
authors.initials: H
authors.lastname: Aoki
authors.forename: Tadashi
authors.initials: T
authors.lastname: Onoda
authors.forename: Shigehiro
authors.initials: S
authors.lastname: Shiozaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ohno
authors.forename: Kenji
authors.initials: K
authors.lastname: Higaki
authors.forename: Norihisa
authors.initials: N
authors.lastname: Takakura
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006498:Hepatectomy; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents